Efficacy and Safety of Guizhi Decoction AssociatedFormulas for Allergic Rhinitis: A Systematic Review
Table 1
Summary of findings.
Intervention
Outcome
No. of trials
Participants (E: male/female)/(C: male/female)
Effect size (RR)
95% CI
value Of effect size
I2 value
GZDAF vs. WM
Recovery rate
5
(154/109)/(138/99)
1.67
1.34 to 2.08
<0.01
0%
Accumulative marked effective rate
9
(269/192)/(247/183)
1.73
1.47 to 2.02
0%
Accumulative marked rate
1.20
1.13 to 1.27
28%
Recurrence rate (3 months)
4
(125/110)/(83/72)
0.14
0.04 to 0.47
30%
Recurrence rate (6 months)
0.20
0.10 to 0.44
34%
Cases of main symptoms disappearance (subgroup 1)
1
(18/14)/(20/12)
1.44
1.02 to 2.05
0.05
NA
Cases of main symptoms disappearance (subgroup 2)
1
(21/19)/(25/15)
2.75
1.68 to 4.51
<0.01
NA
GZDAF + WM vs. WM
Recovery rate
2
A∗
1.26
0.94 to 1.68
0.13
0%
Accumulative marked effective rate
4
B∗
1.13
0.96 to 1.33
Accumulative marked rate
1.22
1.13 to 1.32
<0.01
GZDAF + ABT vs. WM
Recovery rate
1
(52/48)/(27/23)
1.48
1.03 to 2.12
0.03
NA
Accumulative marked effective rate (subgroup 1)
1
(15/15)/(14/16)
0.6
0.25 to 1.44
0.25
NA
Accumulative marked effective rate (subgroup 2)
1
(20/20)/(21/19)
1.67
1.05 to 2.66
0.03
NA
Accumulative marked rate (subgroup 1)
2
(35/35)/(35/35)
1.05
0.94 to 1.17
0.38
0%
Accumulative marked rate (subgroup 2)
1
(20/20)/(21/19)
1.41
1.12 to 1.77
<0.01
NA
GZDAF vs. GZDAF + TCMET
Recovery rate
2
(67/95)/(60/82)
0.78
0.61 to 0.99
0.04
0%
Accumulative marked rate (subgroup 1)
1
(43/77)/(38/62)
0.77
0.66 to 0.89
<0.01
NA
Accumulative marked rate (subgroup 2)
1
(24/18)/(22/20)
0.88
0.77 to 1
0.05
NA
E: experimental group; C: control group; GZDAF: Guizhi Decoction associated formulas; WM: Western medicine; ABT: acupoint-based therapy; TCMET: TCM external therapy; NA: not applicable; A∗: 61 for male (E and C)/53 for female (E and C) in Deng 2011, and (33/34)/(31/26) in Zhang 2017; B∗: 61 for male (E and C)/53 for female (E and C) in Deng 2011, 72 for male (E and C)/62 for female (E and C) in Luo 2016, and (59/38)/(54/53) in Zhang 2017 + Zhu 2015.
